HIV-1 infection in individuals with the CCR5-Δ32/Δ32 genotype: Acquisition of syncytium-inducing virus at seroconversion

Journal of Acquired Immune Deficiency Syndromes

Volumn 29, Issue 3, 2002, Pages 307-313

  Sheppard, Haynes W ^a   Celum, Connie ^a   Michael, Nelson L ^a   O'Brien, Stephen ^a   Dean, Michael ^a   Carrington, Mary ^a   Dondero, Dale ^a   Buchbinder, Susan P ^a  

^a VIRAL AND RICKETTSIAL DISEASE LABORATORY   (United States)

Author keywords

CCR5; CCR5 genotype; CCR5 32 32; Coreceptors; CXCR4; HIV 1; Homozygous 32; NSI; Seroconverters; SI; X4 HIV 1

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DISEASE COURSE; GENE DELETION; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RESISTANCE; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; SEROCONVERSION; VIRUS LOAD; VIRUS PATHOGENESIS;

EID: 0036500559     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200203010-00013     Document Type: Article

References (47)

1. Chemokines and HIV-1 second receptors
2. + T-cell levels
3. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression
4. The natural history of HIV-1 infection: Virus load and virus phenotype: Independent determinants of clinical course?
5. Homozygous defect in HIV-1 co-receptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection
6. Global distribution of the CCR5 gene 32-basepair deletion
7. Distribution of the CCR5 gene 32-bp deletion in Europe
8. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene
9. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the ccr-5 chemokine receptor gene
10. The role of mutant CCR5 allele in HIV-1 transmission and disease progression
11. + lymphocytes from exposed-uninfected individuals: Association with low expression of CCR5 and high production of B-chemokines
12. HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene
13. The extent of genetic variation in the CCR5 gene
14. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression
15. Homozygous and heterozygous CCR5-Δ32 genotypes are associated with resistance to HIV infections
16. Association between CCR5 genotype and the clinical course of HIV-1 infection
17. Early protective effect of CCR-5 delta32 heterozygosity on HIV-1 disease progression: Relationship with viral load
18. HIV-1-infected long-term slow progressors heterozygous for delta32-CCR5 show significantly lower plasma viral load than wild-type slow progressors
19. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro
20. HIV-1 infection in an individual homozygous for the CCR5 deletion allele
21. HIV-1 infection in a man homozygous for CCR5-delta-32
22. HIV-1 infection in an individual homozygous for CCR5Δ32
23. Homozygous 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient
24. HIV-1 infection in a heterosexual man homozygous for CCR-5 Δ32
25. An HIV-1 infected individual homozygous for the CCR-5 Δ32 allele and the SDF-1 3′ A allele
26. The natural history of human immunodeficiency virus infection
27. Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United States
28. Exclusive and persistent use of the entry co-receptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta-32
29. Genetic relationships determined by a heteroduplex mobility assay: Analysis of HIV env genes
30. Feasibility of human immunodeficiency virus vaccine trials in homosexual men in the United States: Risk behavior, seroincidence, and willingness
31. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule
32. Co-receptor usage of primary human immunodeficiency virus type 1 isolates varies according to biologic phenotype
33. The HIV co-receptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes
34. Expression of chemokine receptors CXCR4 and CCR5 in HIV-1 infected and uninfected individuals
35. CXCR-4 is expressed by primary macrophages and supports CCR5-independent infection by dual-tropic but not T-tropic isolates of human immunodeficiency virus type 1
36. Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: Implications for HIV primary infection
37. Primary human immunodeficiency virus type2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in co-receptor usage
38. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development
39. + T-cells provides a mechanism for lifelong persistence of HIV-1 even in patients on effective combination therapy
40. HIV-1 entry inhibitors: Evading the issue
41. CCR5- and CXCR4-tropic HIV-1 are equally cytopathic for their T-cell targets in human lymphoid tissue
42. Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression
43. + T cells by macrophage-tropic HIV envelope
44. + T cell homeostasis and in vitro HIV-1 susceptibility in transgenic mice expressing T cell line-tropic HIV-1 receptors
45. A novel mechanism of CD4 lymphocyte depletion involves effects of HIV on resting lymphocytes: Induction of lymph node homing and apoptosis upon secondary signaling through homing receptors
46. Lymphocyte traffic control by chemokines
47. AIDS as immune system activation: A model for pathogenesis